Perifosine (KRX-0401)

Catalog No.S1037

Perifosine (KRX-0401) is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.

Price Stock Quantity  
USD 147 In stock
USD 270 In stock
USD 870 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Perifosine (KRX-0401) Chemical Structure

Perifosine (KRX-0401) Chemical Structure
Molecular Weight: 461.66

Validation & Quality Control

Cited by 47 publications:

14 customer reviews :

Quality Control & MSDS

Related Compound Libraries

Perifosine (KRX-0401) is available in the following compound libraries:

Akt Inhibitors with Unique Features

  • Selective Akt Inhibitor

    CCT128930 AKT2-selective, IC50=6 nM.

  • Most Potent Akt Inhibitor

    AZD5363 Akt1, IC50=3 nM; Akt2, IC50=8 nM; Akt3, IC50=8 nM.

  • Akt Inhibitor in Clinical Trial

    Ipatasertib (GDC-0068) Phase II for Prostate Cancer and Gastric Cancer.

  • Newest Akt Inhibitor

    AZD5363 Potent inhibitor of all isoforms of Akt (Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM, similar to P70S6K/PKA and lower activity towards ROCK1/2.

Product Information

  • Compare Akt Inhibitors
    Compare Akt Products
  • Research Area

Product Description

Biological Activity

Description Perifosine (KRX-0401) is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.
Targets Akt [1]
(MM.1S cells)
IC50 4.7 μM
In vitro Perifosine develops anti-proliferative properties with IC50 of 0.6-8.9 μM in immortalized keratinocytes (HaCaT), and head and neck squamous carcinoma cells. [1] Perifosine strongly reduces phosphorylation levels of Akt and extracellular signal-regulated kinase (Erk) 1/2, induces cell cycle arrest in G1 and G2, and causes dose-dependent growth inhibition of mouse glial progenitors. [2] Perifosine (10 μM) completely inhibits the phosphorylation of Akt in MM.1S cells. [3] A recent study demonstrates Perifosine induces cell cycle arrest and apoptosis in human hepatocellular carcinoma cell lines by blockade of Akt phosphorylation. [4]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
T24 BC NIO4OVhHfW6ldHnvckBCe3OjeR?=NX\lUVVZOC53L{GvNk42KM7:TR?=MVmzJIg>NF35XI9z\WS3Y3XzJJRp\SCkYYPhcEBESiC2eYLvd4lv\SCyaH;zdIhwenmuYYTpc44hdGW4ZXzzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyM1TKTFI3ODl5OEez
T24 BC M3XNR2NmdGxiVnnhZoltcXS7IFHzd4F6NXj0dmtvOC53L{GvNk42KM7:TR?=NX3zWG5EOjRiaB?=MXvlcohidmOnczDzc5Ji\mWwaXKtbY5lfWOnZDDj[YxtKH[rYXLpcIl1gSCmZXPy[YF{\Q>?M3X1[VI3ODl5OEez
T24 BC NWXCRZNRSXCxcITvd4l{KEG|c4PhfS=>MW[yMlUh|ryPMnrENlQhcA>?MVHz[Y5{cXSrenXzJGJEKGOnbHzzJJRwKHOxcnHm[Y5q[i2rbnT1Z4VlKGGyb4D0c5Rq[8LiMXOyOlA6Pzh5Mx?=
HepG2NEjHdoZHfW6ldHnvckBCe3OjeR?=M322[lIxyqEQvF2=M1jFc|I1yqCqMoPJdJJw\HWlZYOgZY4hcW62ZX7z[UBkgXSxcHzhd41q[yC4YXP1c4xqgmG2aX;uJINwenKnc4DvcoRqdmdidH:gZUBvd3SjYnzlJIRqdGG2YYTpc44hd2ZidHjlJGVTKGOrc4Tldo5{NWTQXXJJOjV7M{SyN|I>
U-87 MG M2Lse2Z2dmO2aX;uJGF{e2G7MmCxNlDDqM7:TR?=M4LmSFI1yqCqMU\pcoNz\WG|ZYOg[I92[mynLX3lcYJz[W6nIHLveY5lKHO2coXjeJVz\XN?MnzKNlU6OzR{M{K=
HepG2M1frcmZ2dmO2aX;uJGF{e2G7M3LTWlIxyqEQvF2=MYG2M|I1KGh?NYqyWmx7cW6lcnXhd4V{KHSqZTDs[ZZmdHNib3[gUGM{NUmLIHPveJJm[XSnZDD3bZRpKEOTNGHYeVQzPTl|NEKzNi=>
U-87 MG MUDGeY5kfGmxbjDBd5NigQ>?NUHNO3R6OjEEoN88US=>NEftNZA3NzJ2IHi=M17lRYlv[3KnYYPld{B1cGVibHX2[Yx{KG:oIFzDN{1KUSClb4Ty[YF1\WRid3n0bEBEWQ>?M4LHOFI2QTN2MkOy
HepG2M3;MeGZ2dmO2aX;uJGF{e2G7NHe3cJAzOMLizszNNFHxN3k3NzJ2IHi=MoPx[IVkemWjc3XzJGxEOy2LSTDk[Ydz[WSjdHnvcuKh\nKxbTC2JIg>NVfzbXJvOjV7M{SyN|I>
U-87 MG MknvSpVv[3Srb36gRZN{[Xl?MXeyNOKh|ryPM1ezNVYwOjRiaB?=MnG0bY5kemWjc3XzJJRp\SCjdYTvdIhi\2mlIH\seZghKGG2IE[gbEB4cGmuZTDpcohq[mm2czD0bIl{KG[udYigZZQhOjSqNFrqR2IzPTl|NEKzNi=>
HepG2NFX4XIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX2yNE81OCEQvF2=M1O3W|I1NzR6IHi=M2T2SolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{Mnr4NlU6OzR{M{K=
U-87 MG NXizXmhsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXyyNE81OCEQvF2=Ml64NlQwPDhiaB?=MYHpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?M4X0T|I2QTN2MkOy
A549NHTQTItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2jMNVAvOy1zMDFOwG0>M1OxTlI1Nzd{IHi=M3\SUolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{NXvYVYNDOjV4OUe4PVk>
H460NEfXc4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2fq[FAvOy1zMDFOwG0>MnL6NlQwPzJiaB?=NWjofolZcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK=Mnv2NlU3QTd6OUm=
A549NHq5XmFCeG:ydH;zbZMhSXO|c3H5NELQWHcyNzNizszNM{LNdVQ5KGh?NVH1NI9ocW6mdXPld{BieG:ydH;zbZM>M13NfVI2Pjl5OEm5
H460NVHMdHNsSXCxcITvd4l{KEG|c4PhfS=>NHzieogyNzNizszNMlzMOFghcA>?MnXrbY5lfWOnczDhdI9xfG:|aYO=NFXqNnczPTZ7N{i5PS=>
A549M4CwRmZ2dmO2aX;uJGF{e2G7NILo[m0{KM7:TR?=NEjYZZY5KGh?NFzFd3NjdG:la4OgRWtVKGGldHn2ZZRqd25?MVOyOVY6Pzh7OR?=
H460M1r3W2Z2dmO2aX;uJGF{e2G7NXX6c3JNOyEQvF2=M1mwe|ghcA>?MY\icI9kc3NiQVvUJIFkfGm4YYTpc44>MXSyOVY6Pzh7OR?=
A549MXrGeY5kfGmxbjDBd5NigQ>?M{C3NFMh|ryPNEHvUpY5KGh?MXPicI9kc3NibWTPVmMyNCCjbnSgSXJMNU2DUFugZYN1cX[jdHnvckBkd22kaX7l[EB4cXSqIF3FT{0yPjJ?M3ziSFI2Pjl5OEm5
H460MVPGeY5kfGmxbjDBd5NigQ>?NFLPVGM{KM7:TR?=MoXHPEBpNXvReGdG[myxY3vzJI1VV1KFMTygZY5lKEWUSz3NRXBMKGGldHn2ZZRqd25iY3;tZolv\WRid3n0bEBOTUtvMU[yNYDocVI6OjV4OUe4PVk>
RMG1MVTD[YxtKF[rYXLpcIl1gSCDc4PhfS=>NHfJOpAyNTNyIN88US=>MXu3NkBpNH\VS4Rl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK=NH3Cd4MzPTVzOUG0PC=>
RMG2MkfkR4VtdCCYaXHibYxqfHliQYPzZZk>MWGxMVMxKM7:TR?=NU\pPJozPzJiaB?=MWPk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?NFjlN2kzPTVzOUG0PC=>
KOC7CNH;ING1E\WyuIG\pZYJqdGm2eTDBd5NigQ>?MWixMVMxKM7:TR?=NXnnNXBDPzJiaB?=NX;1cmY{\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXyMUSyOVUyQTF2OB?=
HAC2M2O2SmNmdGxiVnnhZoltcXS7IFHzd4F6NHnofHMyNTNyIN88US=>NXfQSFZRPzJiaB?=MULk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?Mm\ZNlU2OTlzNEi=
RMG2NUXoVohES2WubDDWbYFjcWyrdImgRZN{[Xl?M4fV[VEuOzBizszNMoTPOFghcA>?MWDk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?NV;pTJRvOjV3MUmxOFg>
OVISENVXzRYdTS2WubDDWbYFjcWyrdImgRZN{[Xl?M4nLRVEuOzBizszNMl:0OFghcA>?NF7ZU|ll\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK=MmnxNlU2OTlzNEi=
SKOV3MUTD[YxtKF[rYXLpcIl1gSCDc4PhfS=>NVfnSXppOS1|MDFOwG0>NV7VPJdZPDhiaB?=MXHk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?NVHQV4RCOjV3MUmxOFg>
A2780NYq3e3BLS2WubDDWbYFjcWyrdImgRZN{[Xl?NWOwOnA{OS1|MDFOwG0>NFnuVI81QCCqNUjiWXpr\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXyMmKyNlU2OTlzNEi=
RMG1NFjI[3VCeG:ydH;zbZMhSXO|c3H5MWSzNEDPxE1?MUCyOEBpNI\sVlBqdmS3Y3XzJIFxd3C2b4Ppdy=>NXzSenFiOjV3MUmxOFg>
RMG2NUjzVGpQSXCxcITvd4l{KEG|c4PhfS=>M2PXZ|MxKM7:TR?=MUKyOEBpMXPpcoR2[2W|IHHwc5B1d3Orcx?=NH3pT5MzPTVzOUG0PC=>
HCC1806MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4XI[FAuOTBizszNM2XWdVQ5KGh?NHLOdYtGSzVyPUKuPFTjiIoEsfMAjVAvODdizszNMUWyOVI6OzV5Nh?=
MDA-MB-231 NVnqe4hpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MViwMVExKM7:TR?=NFLSTW01QCCqMlzHSWM2OD1zLkGz5qCKyrIkgJmwMlA4KM7:TR?=NIHhV2szPTJ7M{W3Oi=>
GL-1MorWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXuwMlHjiJNzMEFihKnPxE1?M2fWbFQ5KGh?M4DROWlEPTB;OT65NUDPxE1?NGCyNXgzPDh6MUWwPC=>
CLBL-1MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXfhO3JvOC5z4pETNVAx6oDLzszNMnLSOFghcA>?NHPUO2xKSzVyPUOzMlAh|ryPNYW2dYNZOjR6OEG1NFg>
UL-1M3;hbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFXo[XIxNjIkgKOxNFDjiIoQvF2=NGjqe2s1QCCqMlT2TWM2OD15LkCxJO69VQ>?MYWyOFg5OTVyOB?=
EmaNYTTZnBbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml;XNE4y6oDVMUCw5qCK|ryPM4Lnc|Q5KGh?NGr2ZY5KSzVyPUW4Mlch|ryPNGrxN5AzPDh6MUWwPC=>
PANC-1NHTnVJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mnq3NE0zPSEQvF2=NV;zcJNlPzJiaB?=M2L5dYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVzM3jjTVI1PTF7N{Wx
MIAMlfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NW\0TFlCOC1{NTFOwG0>MlvhO|IhcA>?M3\JVolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVzNX:0eoJ5OjR3MUm3OVE>
AsPC-1M2ezSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIm4cnUxNTJ3IN88US=>NH7L[Wg4OiCqNHiwc5VqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?M3nvWFI1PTF7N{Wx
PANC-1NH3Jb|BHfW6ldHnvckBCe3OjeR?=M3j2OFAvPSEQvF2=MYWyOEBpMX;pcohq[mm2czDBb5QtKFN4S{GsJIFv\CCHcnuxM|IheGixc4Doc5J6dGG2aX;uxsA>NWL2fpVyOjR3MUm3OVE>
MIAMnrjSpVv[3Srb36gRZN{[Xl?MVKwMlUh|ryPMkLvNlQhcA>?M37RO4lvcGmkaYTzJGFsfCxiU{\LNUwh[W6mIFXyb|EwOiCyaH;zdIhwenmuYYTpc47DqA>?NET4UHMzPDVzOUe1NS=>
AsPC-1M4TQSmZ2dmO2aX;uJGF{e2G7MWOwMlUh|ryPMoHVNlQhcA>?MlnwbY5pcWKrdIOgRYt1NCCVNluxMEBidmRiRYLrNU8zKHCqb4PwbI9zgWyjdHnvcuKhMVeyOFUyQTd3MR?=
U87MGM1ThTmNmdGxiVnnhZoltcXS7IFHzd4F6NET6eFIxNTJ3IN88US=>NUjCcI9KOjRvOU[gbC=>M4PKUYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=>NG\G[2YzPDB4NUWyNi=>
SGC7901 NHXuWY5HfW6ldHnvckBCe3OjeR?=MXGwMlc2NzFywrFOwG0>M2nlZ|Q5KGh?M33HZoRm[3KnYYPld{BxNUGtdDCoV4VzKDR5MzmsJJAuT1ONM98yJEhU\XJiOTmsJIFv\CCFLV3ZR{Bt\X[nbIRCpC=>NUnFTI1{OjN7MUKyOFY>
MGC803 M2DyVmZ2dmO2aX;uJGF{e2G7NI[3fpUxNjd3L{GwxsDPxE1?MorKOFjDqGh?NWraUnE{\GWlcnXhd4V{KHBvQXv0JEhU\XJiNEezLUwheC2JU1uz{tIhMFOncjC5LUwh[W6mIFOtUXlEKGyndnXsd:KhNUHFS2JwOjN7MUKyOFY>
TykNuMn7wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlPwTWM2OD1|LkWg{txONGPEZ5QzOzh5N{CxNi=>
TykNuRM3vMZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVPJR|UxRTVwNTFOwG0>NUfIW|VYOjN6N{ewNVI>
M41MlfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVrRWI51UUN3ME2yOE44KM7:TR?=NVjifIs2OjN6N{ewNVI>
M41RMonXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1TkfmlEPTB;MUmuPEDPxE1?MXWyN|g4PzBzMh?=
OVCAR8MnrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmnKTWM2OD1|MT6xJO69VQ>?MofVNlM5PzdyMUK=
HeyA8NYPJW|hpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2LoPGlEPTB;MkSuN{DPxE1?M4nzb|I{QDd5MEGy
A2780CPMYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVPreJRjUUN3ME23MlYh|ryPM{nQfVI{QDd5MEGy
OVCAR5MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1\TZmlEPTB;Nj63JO69VQ>?M1G4OlI{QDd5MEGy
A2780SMlvSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnT4TWM2OD1zND61JO69VQ>?MoixNlM5PzdyMUK=
MCASMkXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mke2TWM2OD1zMj61JO69VQ>?NIHsdmUzOzh5N{CxNi=>
NCI-H727Mlv6R4VtdCCYaXHibYxqfHliQYPzZZk>MlT0NE0yODBizszNNXLNcFhsOjRxN{KgbC=>MlXl[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIJwfGhiZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXyMVmyNlQ6QTR|Nx?=
GOT1M17IZ2NmdGxiVnnhZoltcXS7IFHzd4F6MofwNE0yODBizszNM4ftVFI1Nzd{IHi=NEfVcFFl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfCCvYX7u[ZI>NF3sRlMzOjR7OUSzOy=>
BON1NFnZZWNE\WyuIG\pZYJqdGm2eTDBd5NigQ>?M4H6ZVAuOTByIN88US=>Mnm5NlQwPzJiaB?=MX\k[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK=M1HkWVIzPDl7NEO3
BON1Mk[5RZBweHSxc3nzJGF{e3OjeR?=MYCwMVExKM7:TR?=MXWyOEBpMk\lbY5lfWOnczDhdI9xfG:|aYOg[I9{\SCmZYDlcoRmdnSueR?=M2\lc|IzPDl7NEO3
BON1MVnGeY5kfGmxbjDBd5NigQ>?MUG3MlUwOTBizszNM{frW|ghcA>?MnnJ[IVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJJRp\SCjboTpMYFxd3C2b4TpZ{Bxem:2ZXnud{BDS0x{IHHu[EBD[2xvWFy=M2jydVIzPDl7NEO3
Kasumi-1MYXD[YxtKF[rYXLpcIl1gSCDc4PhfS=>MoDlNE0zOCEQvF2=MmDXNlQwPDhiaB?=M2nqRoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=>MoGwNlI1ODd{Mki=
HL-60NHLN[25E\WyuIG\pZYJqdGm2eTDBd5NigQ>?MVewMVIxKM7:TR?=M{jWVFI1NzR6IHi=MofO[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIJwfGhiZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXyNFn1T3YzOjRyN{KyPC=>
Kasumi-1NWDGd3pwSXCxcITvd4l{KEG|c4PhfS=>NHiydIgyOCEQvF2=MW[yOEBpM4n6dIlv\HWlZYOgZZBweHSxc3nzNWTSOYNyOjJ2MEeyNlg>
HL-60NV7nNHE{SXCxcITvd4l{KEG|c4PhfS=>NX\XNoJjOTBizszNMnLaNlQhcA>?MlG2bY5lfWOnczDhdI9xfG:|aYO=MkDoNlI1ODd{Mki=
Kasumi-1NHflTVRHfW6ldHnvckBCe3OjeR?=M1uyOVIvPS93L{GwJO69VQ>?NEHNRY0zPCCqM4fkToRm[3KnYYPld{BCc3RiYX7kJJAuSWu2IHzleoVte8LiZH;z[U1l\XCnbnTlcpRtgQ>?M1PuR|IzPDB5MkK4
HL-60MXfGeY5kfGmxbjDBd5NigQ>?NULwdoRIOi53L{WvNVAh|ryPMVuyOEBpMn\B[IVkemWjc3XzJGFsfCCjbnSgdE1Cc3RibHX2[Yx{yqCmb4PlMYRmeGWwZHXueIx6Mn3jNlI1ODd{Mki=
Kasumi-1MlnVSpVv[3Srb36gRZN{[Xl?NYO3XIdtOi53L{WvNVAh|ryPMY[yOEBpNIDwSo1qdmS3Y3XzJJRp\SCyaH;zdIhwenmuYYTpc44hd2ZiSl7LNU8zKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVzNVLwN4ZqOjJ2MEeyNlg>
HL-60NV;hXnRWTnWwY4Tpc44hSXO|YYm=MlPoNk42NzVxMUCg{txOM3vUV|I1KGh?MnHtbY5lfWOnczD0bIUheGixc4Doc5J6dGG2aX;uJI9nKEqQS{GvNkBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=>NEPFVIYzOjRyN{KyPC=>
K562MmnDSpVv[3Srb36gRZN{[Xl?Mmn1NlAh|ryPMmW2OFghcA>?MnvHbY5lfWOnczDheZRweGijZ4pCpC=>M3X2eVIzPDB5MkK4
OCUT1NIf4e2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVPzR5ZyOC5zLUOg{txOMljrOUBlMl;zbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI>NH3CWogzOjB7MEK3NS=>
K1MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2nsTVAvOS1|IN88US=>MlXsOUBlMljRbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI>M2nVOlIzODlyMkex
OCUT1M3T4WmZ2dmO2aX;uJGF{e2G7MlPMN{DPxG1?MmD3NlQhcA>?M4fpN4NifXOnczDhJIRz[W2jdHnjJIlv[3KnYYPlJIlvKEd{L12gdIhie2V?MV[yNlA6ODJ5MR?=
CaOV3NXu0SJprS2WubDDWbYFjcWyrdImgRZN{[Xl?NIO2fYkyNzVxMUCg{txONVnlNZlCPDhiaB?=Mory[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{IHPveJJm[XSnZDD3bZRpKHCjY3zpeIF5\Wx?NWj1VpRUOjF5N{WwOVQ>
SKOV3MWLDfZRwfG:6aXPpeJkhSXO|YYm=NXPQe|c1PSEQvF2=M1XHT|Q5KGh?M4XCbIVvcGGwY3XzJJBi[2yrdHH4[YwhcW6mdXPl[EBwfmG{aXHuJINidmOncjDj[YxtKGSnYYToxsA>M{SyZVIyPzd3MEW0
A2780M33qd2N6fG:2b4jpZ4l1gSCDc4PhfS=>NW\MRnZZPSEQvF2=NH;tfVQ1QCCqNFjqeXZmdmijbnPld{Bx[WOuaYThfIVtKGmwZIXj[YQhd3[jcnnhckBk[W6lZYKgZ4VtdCCmZXH0bOKhNInlRZEzOTd5NUC1OC=>
HT-29 M{LM[WN6fG:2b4jpZ4l1gSCDc4PhfS=>M2HSR|Uh|ryPMnvpOFghcA>?NGD1V3RmdmijbnPld{Bx[WOuaYThfIVtKGmwZIXj[YQhd3[jcnnhckBk[W6lZYKgZ4VtdCCmZXH0bOKhMUiyNVc4PTB3NB?=
A498MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MknVNE01OCEQvF2=NVvNb4JpPzJiaB?=NHv0W|NqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?MkLONlE3PDRyNUC=
CAKI-1MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXnR[FdMOC12MDFOwG0>NVjZTJY1PzJiaB?=MXfJR|UxhjFyIN88US=>NYLZZ4hSOjF4NESwOVA>
769-PNGH2PXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3u5d|AuPDBizszNNIOwVFQ4OiCqM37nS2lEPTC-NT2xNEDPxE1?NHL2b5EzOTZ2NEC1NC=>
786-0MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEi1[4MxNTRyIN88US=>NEPxUXc4OiCqMWLJR|UxhjVizszNMle2NlE3PDRyNUC=
786-OMknLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUCwMVIxKM7:TR?=NWfMeYlyPzJiaB?=NXTCSG9ycW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?NU\iV25YOjF4NESwOVA>
CAKI-1MlL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYGwMVIxKM7:TR?=NHzicJA4OiCqNH;FflNqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?M17mZ|IyPjR2MEWw
769-PNUXybnJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV6wMVIxKM7:TR?=Mn3yO|IhcA>?NGPrZ3ZqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?NVi4VpFEOjF4NESwOVA>
A498MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV[wMVIxKM7:TR?=MnrqO|IhcA>?NHfC[5pqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?M2XKTlIyPjR2MEWw
CWR22RV1MUnD[YxtKF[rYXLpcIl1gSCDc4PhfS=>MVixNEDPxE1?NYXJd|dlOjRiaB?=M3jwcIlv[3KnYYPld{B{\W6|aYTpeol1gSCxZjDoeY1idiCFV2KyNnJXOSClZXzsd{B1dyC{YXTpZZRqd25?NIrE[28zOTR7NkK3Ny=>
CWR22RV1NIG5VYxCeG:ydH;zbZMhSXO|c3H5NFLYXI0yOCEQvF2=NVzxSZp5OjRiaB?=MWPlcohidmOnczDyZYRq[XSrb36gbY5lfWOnZDDhdI9xfG:|aYO=Ml70NlE1QTZ{N{O=
CWR22RV1NUT3OYZMTnWwY4Tpc44hSXO|YYm=NYrJOWE1PSEQvF2=MnXENlQhcA>?NF3vUpFz\WS3Y3XkJJBpd3OyaH;yfYxifGmxbjDv[kBCc3Ric3nncolncWOjboTsfS=>NX3PW|lXOjF2OU[yO|M>
HepG2 MkW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{XlPFUwOTBxMkCvOFAh|ryPM13yR|I1NzR6L{eyJIg>MlfhbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ?MmfvNlA5PDJ2MkW=
Bel-7402MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MofNOU8yOC9{MD:0NEDPxE1?MYqyOE81QC95MjDoNI[4bWlqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=NXLsflNuOjB6NEK0NlU>
HepG2 NUHmeGJUTnWwY4Tpc44hSXO|YYm=NEXEfXc2NzFyL{KwJO69VQ>?Mof0NlQhcA>?NVjUd|VIemW|dXz0d{BqdiC2aHWgZYNkfW23bHH0bY9vKG:oIHPlcIwhdnWvYnXyJIlvKHSqZTDHNk9OKHCqYYPlNW\HSHFtOjB6NEK0NlU>
Bel-7402MkDnSpVv[3Srb36gRZN{[Xl?NYPieI1HPS9zMD:yNEDPxE1?NVvEUnJPOjRiaB?=M{GyR5Jme3WudIOgbY4hfGinIHHjZ5VufWyjdHnvckBw\iClZXzsJI52dWKncjDpckB1cGViR{KvUUBxcGG|ZR?=NIfz[IszODh2MkSyOS=>
HepG2 M3T4OGFxd3C2b4Ppd{BCe3O|YYm=NInwUZo2NzFyL{KwJO69VQ>?NHHwSFMzPC92ODDoNIjF[XhqdmS3Y3XzJIFxd3C2b4Ppd{BifCC2aHWgcI9v\y22aX3lJIV5eG:|dYLlM{LJSlIxQDR{NEK1
Bel-7402NGjkdJBCeG:ydH;zbZMhSXO|c3H5NGTHS|M2NzFyL{KwJO69VQ>?NYnoSWNKOjRxNEigbC=>NVPRb3JVcW6mdXPld{BieG:ydH;zbZMh[XRidHjlJIxwdmdvdHnt[UBmgHCxc4Xy[S=>NHnoZYgzODh2MkSyOS=>
OAW-42M1LYd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYCwMVQxKM7:TR?=M1nLc|czyqCqMYDJR|UxhjFyIN88UUwhcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?MYSyNFQxPTJ7Nh?=
PA-1 MmDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWSwMVQxKM7:TR?=MnXNO|LDqGh?MkDTTWM2OH5{NTFOwG0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{MUOyNFQxPTJ7Nh?=
SKOV3 M3[3T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4q3flAuPDBizszNMV23NuKhcA>?MoPJTWM2OH5|MDFOwG0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{MWWyNFQxPTJ7Nh?=
A2780NF6zdFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3fyTlAuOjBizszNMoD4OFgwPzJiaB?=MVzJR|UxyqB;wrCzxsDPxG1?NUDRXHY1OjB2MEWyPVY>
A2780cis MoLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmLaNE0zOCEQvF2=MnTzOFgwPzJiaB?=NEfySG9KSzVywrC9xsA3yqEQvH2=MWSyNFQxPTJ7Nh?=
SKW6.4MnjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYHRR4FCOi1zMNMg{txONFfYbXU1QMLiaB?=NIjMVZZqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?NEOxTWMzODF|MEm2NC=>
MAVERMXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVGyMVExyqEQvF2=NV3WZ3Z4PDkEoHi=MVzpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=>NX[yeHB[OjBzM{C5OlA>
BJABNFPwTlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVmyMVExyqEQvF2=MWe0POKhcA>?MXzpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=>NU\tcHNPOjBzM{C5OlA>
OCIM3zVcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWWyMVExyqEQvF2=NVLUbVdVPDkEoHi=MU\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=>M{[yXVIxOTNyOU[w
MOLMMUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4Xkb|IuOTEEoN88US=>NWnET3VGPDkEoHi=NGSwRm5qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?MVyyNFE{ODl4MB?=
HL-60NXvHem9oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3HiSFIuOTEEoN88US=>MXi0POKhcA>?M4DUcIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVzNGTDdJkzODF|MEm2NC=>
SKW6.4MXXBdI9xfG:|aYOgRZN{e2G7MWWxNOKh|ryPNVXHRWprOjRxNEigbC=>M3;E[Ylv\HWlZYOgZZBweHSxc3nzJJRqdWVvZHXw[Y5l\W62bIm=MV2yNFE{ODl4MB?=
MAVERMnjDRZBweHSxc3nzJGF{e3OjeR?=NXPOTY52OTEEoN88US=>NXrMT3pHOjRxNEigbC=>M2nwNIlv\HWlZYOgZZBweHSxc3nzJJRqdWVvZHXw[Y5l\W62bIm=MmLmNlAyOzB7NkC=
BJABMlPORZBweHSxc3nzJGF{e3OjeR?=NVLGfIQ{OTEEoN88US=>MnvGNlQwPDhiaB?=Mn6zbY5lfWOnczDhdI9xfG:|aYOgeIlu\S2mZYDlcoRmdnSueR?=MYiyNFE{ODl4MB?=
OCIM4XifGFxd3C2b4Ppd{BCe3O|YYm=MonNNVDDqM7:TR?=Mm\QNlQwPDhiaB?=NYjNVo1XcW6mdXPld{BieG:ydH;zbZMhfGmvZT3k[ZBmdmSnboTsfS=>MoPONlAyOzB7NkC=
MOLMM1vzUWFxd3C2b4Ppd{BCe3O|YYm=NWnVO5FLOTEEoN88US=>NY[0eJpROjRxNEigbC=>M1r5bolv\HWlZYOgZZBweHSxc3nzJJRqdWVvZHXw[Y5l\W62bIm=NUC3dldOOjBzM{C5OlA>
HL-60MofuRZBweHSxc3nzJGF{e3OjeR?=MlLvNVDDqM7:TR?=NXTWUmh4OjRxNEigbC=>M4fuOolv\HWlZYOgZZBweHSxc3nzJJRqdWVvZHXw[Y5l\W62bIm=MWWyNFE{ODl4MB?=

... Click to View More Cell Line Experimental Data

In vivo Perifosine combining with temozolomide reduces tumor proliferation (a PDGF-driven gliomagenesis) in vivo. The results indicate that Perifosine is an effective drug in gliomas in which Akt and Ras-Erk 1/2 pathways are frequently activated, and may be new candidate for glima treatment in the clinic. [2] Both oral daily and weekly administration of Perifosine significantly reduce human MM tumor growth and increase survival, compared with control animals treated with PBS vehicle only. [3] Perifosine induces thrombocytosis and leukocytosis and increases myelopoiesis in murine marrow and spleen, whereas it causes apoptosis in myeloma xenografts. [5]
Features

Protocol(Only for Reference)

Kinase Assay: [3]

Akt kinase assay MM.1S cells are cultured in the presence or absence of perifosine (5 μM, 6 hours) and then stimulated with IL-6 (20 ng/mL, 10 minutes). In vitro akt kinase assay is then carried out using the Akt Kinase Assay Kit.

Cell Assay: [2]

Cell lines Human glioma cell lines
Concentrations 0, 15, 30 and 45 μM
Incubation Time 48 hours
Method Cells are incubated in the medium with 10% FCS for 48 hours with indicated concentration of Periosine. Cell viability is determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. (Cell Proliferation Kit I; Roche). The absorbance at 590 nm is recorded using the 96-well plate reader.

Animal Study: [3]

Animal Models MM.1S MM cells are inoculated subcutaneously in the right flank of Beige-nude-xid (BNX) mice (5 to 6 weeks old).
Formulation 0.9% NaCl solution
Dosages 250 mg/kg/wk or 36 mg/kg/d
Administration Oral gavage

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Vyomesh Patel, et al. Cancer Res, 2002, 62(5), 1401-1409

[2] Momota H, et al. Cancer Res, 2005, 65(16), 7429-7435.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-07-30)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02238496 Recruiting Brain Tumor, Recurrent|Glioblastoma|Anaplastic Astrocytoma|Anaplastic Oligodendroglioma|Mixed Glioma Andrew Lassman|Pfizer|AEterna Zentaris|Columbia University July 2014 Phase 2
NCT01224730 Active, not recruiting Cancer AEterna Zentaris January 2012 Phase 1
NCT01097018 Completed Colorectal Cancer AEterna Zentaris April 2010 Phase 3
NCT01049841 Active, not recruiting Pediatric Solid Tumors Memorial Sloan Kettering Cancer Center|University of Wisc  ...more Memorial Sloan Kettering Cancer Center|University of Wisconsin, Madison|Duke University|NATL COMP CA NETWORK|Pfizer|AEterna Zentaris January 2010 Phase 1
NCT01051557 Active, not recruiting Adult Anaplastic Astrocytoma|Adult Anaplastic Oligodendroglioma|Adult Diffuse Astrocytoma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gl  ...more Adult Anaplastic Astrocytoma|Adult Anaplastic Oligodendroglioma|Adult Diffuse Astrocytoma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Adult Mixed Glioma|Adult Oligodendroglioma|Recurrent Adult Brain Neoplasm National Cancer Institute (NCI) January 2010 Phase 1|Phase 2

view more

Chemical Information

Download Perifosine (KRX-0401) SDF
Molecular Weight (MW) 461.66
Formula

C25H52NO4P

CAS No. 157716-52-4
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms NSC639966
Solubility (25°C) * In vitro Water 8 mg/mL (17.32 mM)
Ethanol 15 mg/mL (32.49 mM)
DMSO <1 mg/mL (<1 mM)
In vivo 30% propylene glycol, 5% Tween 80, 65% D5W 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name Piperidinium, 4-[[hydroxy(octadecyloxy)phosphinyl]oxy]-1,1-dimethyl-, inner salt

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Akt Products

  • Afuresertib (GSK2110183)

    Afuresertib (GSK2110183) is a potent, orally bioavailable Akt inhibitor with Ki of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2.

  • AT13148

    AT13148 is an oral, ATP-competitive, multi-AGC kinase inhibitor with IC50 of 38 nM/402 nM/50 nM, 8 nM, 3 nM, and 6 nM/4 nM for Akt1/2/3, p70S6K, PKA, and ROCKI/II, respectively. Phase 1.

  • SC79

    SC79 is a brain-penetrable Akt phosphorylation activator and an inhibitor of Akt-PH domain translocation.

  • MK-2206 2HCl

    MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.

    Features:The first allosteric small molecule inhibitor of Akt to enter clinical development.

  • AZD5363

    AZD5363 potently inhibits all isoforms of Akt(Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM in cell-free assays, similar to P70S6K/PKA and lower activity towards ROCK1/2. Phase 2.

    Features:Moderate preclinical tolerability, and PD characteristics of an AKT inhibitor. Distinct profile from other AKT inhibitors in clinical development.

  • Ipatasertib (GDC-0068)

    Ipatasertib (GDC-0068) is a highly selective pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 5 nM/18 nM/8 nM in cell-free assays, 620-fold selectivity over PKA. Phase 2.

  • GSK690693

    GSK690693 is a pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 2 nM/13 nM/9 nM in cell-free assays, also sensitive to the AGC kinase family: PKA, PrkX and PKC isozymes. Phase 1.

  • A-674563

    A-674563 is an Akt1 inhibitor with Ki of 11 nM in cell-free assays, modest potent to PKA and >30-fold selective for Akt1 over PKC.

    Features:Orally bioavailable compound (achieved by replacing indole of A-443654 with phenyl moiety) and somewhat less selective for Akt over PKA than A-443654.

  • Triciribine

    Triciribine is a DNA synthesis inhibitor, also inhibits Akt in PC3 cell line and HIV-1 in CEM-SS, H9, H9IIIB, U1 cells with IC50 of 130 nM and 20 nM, respectively; does not inhibit PI3K/PDK1; 5000-fold less active in cells lacking adenosine kinase. Phase 1/2.

  • Honokiol

    Honokiol is the active principle of magnolia extract that inhibits Akt-phosphorylation and promotes ERK1/2 phosphorylation. Phase 3.

Recently Viewed Items

Tags: buy Perifosine (KRX-0401) | Perifosine (KRX-0401) supplier | purchase Perifosine (KRX-0401) | Perifosine (KRX-0401) cost | Perifosine (KRX-0401) manufacturer | order Perifosine (KRX-0401) | Perifosine (KRX-0401) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us